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Abstract: Aims High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular
(CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C,
the first cholesterol transport protein (CETP) inhibitor torcetrapib raised blood pressure (BP), impaired
endothelial function, and increased CV mortality and morbidity. Dalcetrapib is a novel molecule acting
on CETP with a different chemical structure to torcetrapib. As HDL stimulates nitric oxide (NO),
suppresses inflammation, and exerts protective CV effects, we investigated the effects of dalcetrapib on
endothelial function, blood pressure, inflammatory markers, and lipids in patients with, or at risk of,
coronary heart disease (CHD) in a double-blind randomized placebo-controlled trial (clinicaltrials.gov
number NCT00655538). Methods and results Patients with target low-density lipoprotein cholesterol
(LDL-C) levels received dalcetrapib 600 mg/day or placebo for 36 weeks on top of standard therapy
(including statins). The primary outcome measures were the change from baseline of flow-mediated
dilatation (%FMD) of the right brachial artery after 5 min of cuff occlusion at 12 weeks and the 24 h
ambulatory blood pressure monitoring (ABPM) at week 4. Secondary outcomes included change from
baseline in FMD after 36 weeks and the change in ABPM at 12 and 36 weeks, changes in HDL-C,
LDL-C, triglycerides, CETP activity, as well as standard safety parameters. Four hundred seventy-six
patients were randomized. Baseline FMD was 4.1 ± 2.2 and 4.0 ± 2.4% with placebo or dalcetrapib,
respectively and did not change significantly from placebo after 12 and 36 weeks (P = 0.1764 and 0.9515,
respectively). After 4, 24, and 36 weeks of treatment with dalcetrapib, CETP activity decreased by
51, 53, and 56% (placebo corrected, all P < 0.0001), while at weeks 4, 12, and 36 HDL-C increased by
25, 27, and 31% (placebo corrected, all P < 0.0001). Low-density lipoprotein cholesterol levels did not
change. At baseline, ABPM was 125 ± 12/74 ± 8mmHg in the placebo and 128 ± 11/75 ± 7mmHg in
the dalcetrapib group (P = 0.3372 and 0.1248, respectively, placebo-corrected change from baseline) and
did not change for up to 36 weeks. Biomarkers of inflammation, oxidative stress, and coagulation did not
change during follow-up except for Lp-PLA2 mass levels which increased by 17% (placebo corrected).
Overall 7 patients given dalcetrapib and 8 patients given placebo experienced at least one pre-specified
adjudicated event (11 events with dalcetrapib and 12 events with placebo). Conclusion The dal-VESSEL
trial has established the tolerability and safety of CETP-inhibition with dalcetrapib in patients with or
at risk of CHD. Dalcetrapib reduced CETP activity and increased HDL-C levels without affecting NO-
dependent endothelial function, blood pressure, or markers of inflammation and oxidative stress. The
dal-OUTCOMES trial (NCT00658515) will show whether dalcetrapib improves outcomes in spite of a
lack of effect on endothelial function
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Aims High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an
attractive therapeutic target. However, in spite of marked elevations in HDL-C, the first cholesterol transport
protein (CETP) inhibitor torcetrapib raised blood pressure (BP), impaired endothelial function, and increased CV
mortality and morbidity. Dalcetrapib is a novel molecule acting on CETP with a different chemical structure to
torcetrapib. As HDL stimulates nitric oxide (NO), suppresses inflammation, and exerts protective CV effects, we
investigated the effects of dalcetrapib on endothelial function, blood pressure, inflammatory markers, and lipids in
patients with, or at risk of, coronary heart disease (CHD) in a double-blind randomized placebo-controlled trial
(clinicaltrials.gov number NCT00655538).
Methods
and results
Patients with target low-density lipoprotein cholesterol (LDL-C) levels received dalcetrapib 600 mg/day or placebo for 36
weeks on top of standard therapy (including statins). The primary outcome measures were the change from baseline of
flow-mediated dilatation (%FMD) of the right brachial artery after 5 min of cuff occlusion at 12 weeks and the 24 h ambu-
latory blood pressure monitoring (ABPM) at week 4. Secondary outcomes included change from baseline in FMD after 36
weeks and the change in ABPM at 12 and 36 weeks, changes in HDL-C, LDL-C, triglycerides, CETP activity, as well as stand-
ard safety parameters. Four hundred seventy-six patients were randomized. Baseline FMD was 4.1+2.2 and 4.0+2.4%
with placebo or dalcetrapib, respectively and did not change significantly from placebo after 12 and 36 weeks (P ¼ 0.1764
and 0.9515, respectively). After 4, 24, and 36 weeks of treatment with dalcetrapib, CETP activity decreased by 51, 53, and
56% (placebo corrected, all P, 0.0001), while at weeks 4, 12, and 36 HDL-C increased by 25, 27, and 31% (placebo cor-
rected, all P, 0.0001). Low-density lipoprotein cholesterol levels did not change. At baseline, ABPM was 125+12/
74+8 mmHg in the placebo and 128+11/75+7 mmHg in the dalcetrapib group (P ¼ 0.3372 and 0.1248, respectively,
placebo-corrected change from baseline) and did not change for up to 36 weeks. Biomarkers of inflammation, oxidative
stress, and coagulation did not change during follow-up except for Lp-PLA2 mass levels which increased by 17%
(placebo corrected). Overall 7 patients given dalcetrapib and 8 patients given placebo experienced at least one pre-speci-
fied adjudicated event (11 events with dalcetrapib and 12 events with placebo).
Conclusion The dal-VESSEL trial has established the tolerability and safety of CETP-inhibition with dalcetrapib in patients with or at
risk of CHD. Dalcetrapib reduced CETP activity and increased HDL-C levels without affecting NO-dependent endo-
thelial function, blood pressure, or markers of inflammation and oxidative stress. The dal-OUTCOMES trial
(NCT00658515) will show whether dalcetrapib improves outcomes in spite of a lack of effect on endothelial function.
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Introduction
Lowering of low-density lipoprotein cholesterol (LDL-C) by inhibi-
tors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (i.e.
statins) is highly effective in improving cardiovascular (CV)
outcome in a broad range of patients.1– 3 However, considerable
residual risk remains, particularly in patients with low high-density
lipoprotein cholesterol (HDL-C).4 Epidemiological and experimen-
tal data support a protective role for HDL-C against atheroscler-
otic vascular disease. Thus, drugs which increase HDL-C would
provide a therapeutic opportunity to reduce further CV events
further.
Targeting the activity of the cholesteryl ester transfer protein
(CETP), a plasma protein that promotes transfer of cholesteryl
esters from protective HDL-C to atherogenic LDL particles, is a
promising approach to increase HDL-C.5 The first CETP inhibitor,
torcetrapib,6 substantially increased HDL-C, but unexpectedly led
to an increased mortality in a large outcome trial.7 Subsequent
studies showed that torcetrapib has a number of ‘off-target’
effects, including increases in blood pressure (BP), in the release
of aldosterone and endothelin, and—in experimental models—
marked endothelial dysfunction as well as worsening of angina.8–11
These findings were surprising as HDL-C increases endothelial
nitric oxide (NO) synthase expression,12–15 NO release, and bio-
availability (due to its superoxide scavenging properties),16 and
augment flow-mediated dilatation (FMD) in patients with hyper-
cholesterolaemia.17 As the untoward effects of torcetrapib were
also observed in animals lacking CETP,9,11,18 they are unlikely to
be related to its action on CETP. Nevertheless, demonstration of
the absence of such off-target toxicity has become a prerequisite
for the development of novel CETP inhibitors.
Dalcetrapib is one of several molecules affecting CETP activ-
ity19,20 that increases HDL-C, apparently without the side effects
of torcetrapib. However, both its CV safety and efficacy remain un-
certain. As the vascular protective effects of HDL-C are mediated
in part by activation of endothelial cells, in particular the release
of NO16 and as torcetrapib specifically worsened this response,
in the dal-VESSEL trial21 we chose to use endothelial function as
assessed by FMD as the primary outcome measure. We enrolled
patients with average or low HDL-C with or at risk of coronary
heart disease (CHD) to exclude ‘torcetrapib-like’ effects in a
non-inferiority trial.
Methods
Study design
The concept and design of the dal-VESSEL trial (see clinicaltrials.gov
number NCT00655538) have been published.21 The study protocol
was approved by the institutional review boards or ethical committees
from participating institutions, respectively. Informed consent was
obtained from all patients before entering the trial. Eligible patients
with CHD or CHD risk equivalent and HDL-C ,50 mg/dL were
required to be treated with statins or ezetimibe to a LDL-C level
,100 mg/dL. Four hundred seventy-six patients were randomized
1:1 between June 2008 and August 2009 to either placebo or dalcetra-
pib 600 mg/day in a double-blind fashion. The dalcetrapib dose
(600 mg/day) was based on previous studies.19,22,23 Patients were
instructed to take two tablets of 300 mg or placebo daily, respectively,
with a meal.
Randomization and masking
Patients were assigned to one of two treatment groups and stratified
by centre according to a computer-generated global randomization
code. Blinding was maintained through matching placebo and
dalcetrapib tablets, and with regard to participant HDL-C and total
cholesterol levels.
Concomitant treatment
Patients were advised to follow a diet based on The American Heart
Association, National Cholesterol Education Program,24 and received
counselling on life-style modifications. Based on drug–drug interaction
studies, there were no medications which could not be
co-administered with dalcetrapib. However, patients were not
allowed to take fibrates, bile acid sequestrants, niacin, rimonabant, or
any medication (other than statins and lipid-lowering drugs) which
would increase HDL-C levels. Care was taken not to change antihyper-
tensive medication.
Predefined endpoints
The primary outcome parameters were: (i) the change from baseline in
endothelial function in response to dalcetrapib over 12 weeks as
assessed by FMD of the brachial artery using high resolution ultra-
sound and (ii) the change in 24 h ambulatory blood pressure monitor-
ing (ABPM) at 4 weeks. The secondary outcome parameters were the
effects of dalcetrapib on FMD at 36 weeks, the change in ABPM at
12 and 36 weeks, and of the following biomarkers: high-sensitive (hs)
C-reactive protein; interleukin-6 (IL-6); soluble P-selectin (sP-selectin);
soluble E-selectin (sE-selectin); soluble intercellular adhesion
molecule-1; soluble vascular cell adhesion molecule-1; matrix
metalloprotease-3; matrix metalloprotease-9; adiponectin, biomarkers
of oxidation [myeloperoxidase (MPO)], and coagulation [tissue plas-
minogen activator (t-PA); plasminogen activator inhibitor-1 (PAI-1)].
Further, blood lipids, lipoproteins and apolipoproteins, CETP mass
and activity, lipoprotein-phospholipase A2 (LP-PLA2) mass, insulin
sensitivity, sodium, and potassium were determined. Clinical events
recorded during the study were also assessed.
Flow-mediated dilatation
Brachial artery diameter was measured in the right brachial artery
5–10 cm proximal to the antecubital fossa at baseline and after
1 min of forearm occlusion (in %) with a high-resolution ultrasound
probe (Ultrasonix SP ultrasound system and an L14, 10 MHz linear
array broadband transducer).25,26 An especially designed arm-rest
and probe holder was constructed to optimize standardization of
the position of the ultrasound probe. Measurements were obtained
during 1 min, after which the blood pressure cuff was inflated to
250 mmHg in order to interrupt blood supply. Following 5 min of
forearm ischaemia, the cuff was released and a second measurement
was obtained during the following 3 min.
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Blood flow velocity measurements
During FMD measurement, blood flow velocity and heart rate were
continuously monitored by pulsed-wave Doppler and displayed as a
spectral Doppler curve. The velocity time integral (VTI) was measured
(off-line) using custom-made, automated flow analysis software
(Medical Imaging Applications, IA, USA). The VTI was calculated for
each R-wave triggered cardiac cycle as a percent increase from base-
line. Measurements were made three times at baseline (first 60 s of
scan) and during reactive hyperaemia (peak VTI following cuff
release). The FMD flow stimulus during reactive hyperaemia was
expressed as the ratio of peak to baseline volume-flow per minute.
Core laboratories
Flow-mediated dilatation was assessed by a central core laboratory
(London Core Lab, London, UK). Sonographers were trained at two
centralized training sessions by highly experienced teachers and
certified by a pre-specified programme developed by the Core Lab.
Training and study scans were read blindly by expert investigators
using a computer-assisted analysis programme.
Blood chemistry, haematology, and coagulation parameters were
measured in a core laboratory (Quintiles Laboratories Europe, The
Alba Campus, Rosebank, Livingston, EH54 7EG, UK) as were lipid
levels, cytokines, and other biomarkers (MedPace Reference Lab
Europe, Technologielaan 19, 3100 Leuven, Belgium).
Ambulatory blood pressure monitoring recordings were analysed in
a core laboratory (Spacelabs Healthcare, Rosanne House, Parkway,
Welwyn Garden City, Herts, AL8 6JE, UK).
Data monitoring
Imaging data were stored in a central database (Amsterdam Medical
Center, Amsterdam, NL, USA), while the clinical database was with
Quintiles Inc. (Global Headquarters, Durham, NC, USA).
Statistical plan and analysis
The study was designed to test two primary hypotheses:21 that dalce-
trapib is non-inferior to placebo with regard to (i) endothelial function
(by FMD) and (ii) changes in 24 h ABPM. The change from baseline to
12 weeks in brachial artery %FMD was compared between treatment
groups using the intention-to-treat principle and included all patients
randomized with a post-baseline efficacy assessment at 12 weeks.
Patients were assigned to treatment groups as randomized. The pre-
specified boundary for non-inferiority in %FMD of 20.65% for the dif-
ference (dalcetrapib minus placebo) was based on the assumptions
that the average baseline %FMD would be approximately 4–4.5%
and that a .15% relative decrease in FMD in the dalcetrapib arm
after 12 weeks of treatment would indicate a disadvantageous effect
on endothelial function. Based on previous assessments of reproduci-
bility with a standard deviation of %FMD change from baseline of 2%,
200 patients in each treatment group were considered sufficient to
provide 90% power to establish non-inferiority, assuming a two-sided
a of 0.05. To account for a 10% dropout in follow-up, it was planned
to randomize 450 patients. In the event that non-inferiority was
demonstrated, a test for superiority using a two-sided significance
level of 5% was planned. The change in %FMD from baseline to
36 weeks compared between treatment groups was a secondary
outcome parameter. Other secondary outcome parameters included
the effects of 36 weeks’ dalcetrapib treatment on blood lipids, CETP
activity, and biomarkers of inflammation and oxidation. No corrections
for multiple comparisons were made.
The other primary outcome parameter was the change in ABPM
from baseline between treatment groups after 4 weeks’ and all patients
who received at least one dose of study medication were included. The
statistical plan pre-specified that analysis was as randomized,21
however, in the event of patients switching from their initially rando-
mized treatment, they could be assigned to treatment groups as an
as-treated population for analysis purposes. The non-inferiority
margin for the change from baseline (dalcetrapib–placebo) was
+2 mmHg. Assuming a standard deviation of 6 mmHg for the 24 h
ABPM change from baseline, 200 patients in each treatment arm
were considered to be sufficient to establish non-inferiority with
90% power using a two-sided a of 5%. Non-inferiority was to be con-
cluded if the upper limit of the 95% confidence interval (CI) for the
difference (dalcetrapib–placebo) in change from baseline did not
exceed +2 mmHg. Allowing for up to 10% dropouts, enrolment of
450 patients was considered sufficient. Secondary safety endpoints
included change from baseline in mean ABPM after 12 and 36
weeks, adverse events, laboratory parameters, ECG, and vital signs.
Cardiovascular events were recorded and adjudicated by the Clinical
Events Committee (CEC).
For the primary and secondary efficacy and safety analyses, a linear
model was assumed, including treatment and centre (small centres
were grouped together) as fixed effects along with a covariate term
for the baseline value of %FMD or 24 h ABPM. Results are reported
in terms of estimated effect sizes, 95% CIs, and P-values. Baseline char-
acteristics of the intent-to-treat population were compared between
study groups with the use of descriptive statistics.
Between-group differences in %FMD and ABPM were also examined
in pre-specified subgroups: HDL-C≤40 mg/dL, HDL-C. 40 mg/dL,
LDL-C≤80 mg/dL, LDL-C . 80 mg/dL, hypertension, diabetes, and
current smoking. In addition, to confirm the robustness of the
primary analyses, key analyses of FMD and ABPM were repeated
based on imputing missing values using the last observation carried
forward method.
Role of the sponsor
The sponsor participated in discussions regarding the design and
conduct of the study with the steering committee members and pro-
vided logistical support. Data and their analysis were assessed jointly.
T.F.L. developed the initial draft of the manuscript with input from
J.J.P.K. and J.E.D., and all authors were involved in reviewing and revis-
ing the manuscript prior to submission. All members of the steering
committee had full access to the data and final responsibility for the
decision to submit for publication.
Results
Patient characteristics and patient flow
We screened 860 patients from 19 centres. Of which, 476 were
randomized and 466 participated in the trial (Figure 1). Four
patients did not receive treatment and 10 were excluded due to
lack of evaluable efficacy data. This left 472 and 466 patients to
be considered for the safety and intention-to-treat primary
analyses, respectively. The study arms were well balanced with
regards to patient characteristics (Table 1). As primarily subjects
with average or low HDL-C were recruited, males were
predominant in this patient population.
Flow-mediated dilatation
Baseline FMD was 4.1+2.2 and 4.0+ 2.4% in the placebo and dal-
cetrapib groups, respectively, and did not change with dalcetrapib
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for up to 36 weeks (Figure 2). At week 12, the placebo-corrected
change from baseline was 20.23 (20.55, 0.10 95% CI;
P ¼ 0.1764), and the primary endpoint met the pre-specified
non-inferiority criteria. At week 36, the corresponding value
was 20.01 (20.46, 0.43; P ¼ 0.9516). Similarly, FMD did not
differ between predefined subgroups, i.e. patients with low or
high HDL-C, diabetics, hypertensives, or younger (,62 years)
and older patients (.62 years; Supplementary material online,
Table S1).
Blood flow velocity
At baseline, hyperaemia (i.e. VTIp/baseline VTIb) was assessed in
198 patients on placebo and 197 on dalcetrapib. VTIp/VTb was
511+ 201% in the placebo group and 521+ 193% in the
dalcetrapib group. At week 12, the corresponding values were
525+411 and 523+195% (P ¼ 0.7383 for placebo-corrected
change from baseline) and at 36 weeks 540+206 and 524+
201% (P ¼ 0.4381) in the placebo and dalcetrapib groups,
respectively (Supplementary material online, Table S2).
Blood pressure
Ambulatory blood pressure monitoring at weeks 4, 12, and 36 was
unchanged (Figure 3 and Supplementary material online, Table S3).
At baseline, ABPM was 125.2+ 11.7/74.2+8.2 mmHg for the
placebo and 127.6+11.2/74.9+ 7.2 mmHg for the dalcetrapib
group. At week 4, the placebo-corrected change from baseline
was 0.65 (95% CI, 20.68, 1.99; P ¼ 0.3372) for systolic and
0.64 (20.18, 1.45; P ¼ 0.1248) for diastolic BP, and met the
Figure 1 Screening, randomization, and follow-up of study subjects.
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pre-specified non-inferiority criteria for the randomized analysis.
Throughout the trial, ABPM did not change significantly in the
entire population or in predefined subgroups (low vs. high
HDL-C, diabetics vs. non-diabetics, old vs. young). Notably, the
percentage of ‘non-dippers’ (i.e. patients without night-time
blood pressure decrease) was similar at baseline and increased
with placebo, but decreased with dalcetrapib (Supplementary
material online, Table S2).
Lipids
At baseline, HDL-C was 38.4+7.1 and 39.1+ 7.3 mg/dL in the
placebo and dalcetrapib groups, respectively. Dalcetrapib increased
placebo-corrected HDL-C by 25, 27, and 31% at weeks 4, 12, and
36, respectively (all P, 0.0001; to 49.7+11.7, 49.2+10.4 and
50.7+ 12.7 mg/dL; Figure 4, Supplementary material online, Table
S4). After 4, 24, and 36 weeks of treatment with dalcetrapib,
CETP activity (placebo corrected) decreased by 50.9, 52.5, and
56.0%, respectively (all P, 0.0001). Placebo-corrected apolipo-
protein A1 levels increased with dalcetrapib by 9% at week 4
and 10% at weeks 24 and 36 (all P, 0.0001). Placebo-corrected
triglyceride levels decreased by 9 and 14%, respectively
(P, 0.005; from 161+81 to 151+ 83 and 149+ 71 mg/dL, re-
spectively; Figure 4). A small, but significant decrease in LDL-C of
4% (P, 0.05) was observed at week 4 only. Placebo-corrected
apolipoprotein B100 decreased significantly by 4, 3, and 5% at
weeks 4, 24, and 36 (P, 0.05; Figure 4).
Laboratory values
Plasma levels of sodium, potassium, and creatinine did not change
significantly nor did the glucose:insulin ratio (data not shown).
Although a placebo-corrected decrease in haemoglobin A1c of
0.1% was observed at week 36 (P, 0.05), this was due to an
increase with placebo with no change with dalcetrapib.
Markers of inflammation
Plasma levels of hs-C-reactive protein, ICAM-1, VCAM-1, IL-6,
MPO, t-PA, or PAI-1 did not differ at baseline nor during treatment
in both the placebo and dalcetrapib groups. Placebo-corrected
Lp-PLA2 mass increased by 17.4% (without correcting for
HDL-C plasma levels; P, 0.001; Supplementary material online,
Table S5).
Adverse clinical events
Adverse events were mild to moderate in intensity and included
nasopharyngitis and influenza, diarrhoea, back pain, and headache
with similar distribution among the treatment groups (Table 2).
Twenty-three pre-specified positively adjudicated events occurred
in 7 patients given dalcetrapib (11 events) and 8 patients given
placebo (12 events); among them 7 major cardiac events (5 with
placebo and 2 with dalcetrapib) and 16 revascularization
procedures (7 in the placebo and 9 in the dalcetrapib group).
No strokes were noted.
Discussion
The dal-VESSEL trial was undertaken to establish the safety and
vascular efficacy of dalcetrapib in a patient population with CHD
or a CHD equivalent risk profile. It used FMD as the primary
outcome measure as the endothelium is the key signal transducer
for vascular homeostasis and responds rapidly to both toxic and
beneficial influences. Our findings show that, in contrast to torce-
trapib,11 dalcetrapib does not worsen endothelial function, nor
does it raise BP as found with torcetrapib. This together with
other safety data suggests that the large ongoing clinical pro-
gramme investigating the effects of dalcetrapib on atherosclerotic
plaque and CV outcomes should be continued.27
Since the early 1990s, statins have been shown to be highly
effective in reducing major CV events in a series of large-scale
clinical trials. Nevertheless, a considerable risk remains even after
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Table 1 Summary of baseline clinical characteristics
Characteristica Placebo
(n5 234)
Dalcetrapib
(n 5 232)
Age, years 61.9+ 7.92 62.3+ 7.05
Male sex, n (%) 211 (90) 211 (91)
Body-mass index 28.7+ 4.4 29.6+ 4.8
Medical history, n (%)
Coronary heart disease 155 (66) 147 (63)
Symptomatic carotid artery
disease
18 (8) 16 (7)
Peripheral arterial disease 16 (7) 24 (10)
Abdominal aortic aneurysm 5 (2) 6 (3)
Type II diabetes 102 (44) 108 (47)
Hypertension 175 (75) 171 (74)
Smoker, n (%)
Ever 191 (82) 181 (78)
Current 57 (24) 65 (28)
Previous or concomitant treatmentb
Statin, n (%) 228 (97) 223 (94)
Angiotensin converting enzyme
inhibitor, n (%)
86 (36) 89 (38)
Angiotensin receptor antagonist,
n (%)
65 (28) 68 (29)
Salicylatesc, n (%) 147 (62) 154 (65)
Calcium channel antagonist, n (%) 70 (30) 66 (28)
Systolic BP, mmHgd 134.6+ 14.95 135.5+ 13.58
Diastolic BP, mmHgd 78.9+ 9.45 80.1+ 7.92
Plasma lipid profile
HDL-C, mmol/L 0.995+ 0.185 1.013+ 0.190
apoA-I, g/L 1.333+ 0.189 1.347+ 0.178
LDL-C, mmol/L 2.051+ 0.457 2.108+ 0.553
apoB, g/L 0.874+ 0.170 0.895+ 0.185
Total cholesterol, mmol/L 3.802+ 0.563 3.945+ 0.665
Triglycerides, mmol/L 1.654+ 0.733 1.819+ 0.916
aAll reported as mean+ SD unless otherwise stated.
bPatients with at least one treatment, multiple occurrences of the same treatment
in one individual counted only once.
cIncludes aspirin, carbasalate calcium, and aspirin DL-lysine.
dMeasured using the auscultatory method.
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achieving marked LDL-C reduction. In epidemiological studies,
HDL-C levels are inversely related to CV risk.1,28,29 Of note, this
relationship is maintained even at very low LDL-C levels as
achieved with the use of high-dose statin therapy.4 These data,
together with experimental work documenting beneficial effects
of HDL-C on endothelial NO synthase expression and NO
release,12–16 the adhesion of white blood cells to the vessel
wall,30,31 and tissue factor expression,32 has made HDL-C
elevation an attractive target for drug therapy.
Infusion of reconstituted HDL in patients with hypercholesterol-
aemia improves endothelial function both in conduit arteries as
well as in the microcirculation.17 In patients with CAD, subcutane-
ous injection of apolipoprotein A1 Milano over 5 weeks resulted in
an increase in HDL-C and a reduced plaque volume as measured
by intravascular ultrasound.33 Since endothelial dysfunction
precedes atherosclerosis,34,35 these findings suggest that HDL-C
exerts protective effects on the vasculature by activating the
L-arginine/NO-pathway and in turn by reducing atherosclerotic
plaque formation.
Recently, drugs which act as modulators or inhibitors of
the CETP have been developed.19,20,36,37 Cholesterol transport
protein is a plasma protein that promotes the transfer of choles-
terol esters from protective HDL to atherogenic LDL particles.
Cholesterol transport protein inhibitors thereby produce large
and consistent elevations of plasma HDL-C levels. However, the
first compound of this type, torcetrapib, unexpectedly increased
mortality in the large ILLUMINATE trial7 in spite of marked
increases in HDL-C and decreases in LDL-C plasma levels. Fur-
thermore, in the RADIANCE-trial,38 using B-mode carotid ultra-
sound as well as in the ILLUSTRATE-trial39 using coronary
intravascular ultrasound, torcetrapib did not reduce carotid intima-
media thickness nor coronary plaque volume. Numerous studies
have subsequently shown toxic ‘off target’ actions of torcetrapib,
including elevations of plasma aldosterone,8,11,18 vascular endothe-
lin tissue levels,9,11 and blood pressure7 together with impaired
endothelial function.11
The BP elevation observed with torcetrapib is not due to CETP
inhibition itself, but is related to its specific molecular structure as
other molecules of this class lack such effects.8,18,40,41 Further-
more, CETP inhibitors have divergent pharmacological properties
and potency on lipid subfractions. In the dal-VESSEL trial, using
dalcetrapib we found an increase in HDL-C of 31%, which is less
than that reported for torcetrapib (72%)7 or anacetrapib
(138%),42 respectively. Low-density lipoprotein cholesterol did
not change in contrast to torcetrapib and anacetrapib which
lower LDL-C by 25 and 40%, respectively.7,42 The increase in
Lp-PLA2 mass of 17% seen with dalcetrapib is likely related to
the increase in HDL-C itself. These results suggest important
pharmacological differences of these agents which may act as
either inhibitors or modulators of CETP.43
Nevertheless, doubt has been cast on the rationale and safety of
CETP inhibition as a therapeutic strategy. Thus, carefully designed,
clinical programmes to determine the safety and efficacy of CETP
inhibitors with the next generation of agents that target CETP are
crucial. The dal-VESSEL trial is the first of a large portfolio of
studies which are evaluating the impact of dalcetrapib on
endothelial function and blood pressure (dal-VESSEL), plaque
volume (dal-PLAQUE 1 and 2; clinicaltrials.gov number
NCT00655473), and CV outcome (dal-OUTCOMES; clinicaltrials.
gov number NCT00658515).27
In dal-VESSEL, endothelial function was chosen as a primary
outcome, because the endothelium represents a key signal trans-
ducer linking circulating factors with the biology of the vessel
wall and precedes and predicts atherosclerosis and clinical
outcome.44– 47 It responds rapidly to beneficial and harmful
stimuli and thus is expected to change in the presence of damaging
Figure 2 Flow-mediated dilatation (FMD) of the brachial artery in percent change from baseline as assessed by high resolution ultrasound of
the brachial artery in patients on placebo (——; n ¼ 234) or dalcetrapib (– – ; n ¼ 232). Data are mean+ SD.
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effects secondary either to the molecule itself or to CETP inhib-
ition. Flow-mediated dilatation has been shown to respond to
pharmacological and dietary interventions. The changes in vascular
reactivity to flow parallel other functions of the endothelium, in-
cluding adhesion of white blood cells, inflammation, and coagula-
tion.48 The use of FMD in pharmaceutical trials has been limited
by challenges of standardization of image acquisition and analysis
as well as the innate biological variability of the measure itself. dal-
VESSEL is the first multicentre trial to use FMD as a primary
outcome measure. Flow-mediated dilatation is an appropriate end-
point as in a rodent model torcetrapib increased the vascular tissue
levels of endothelin and reactive oxidant species, decreased eNOS
expression and NO release, and impaired endothelium-dependent
relaxation.11 As expected in our high-risk patient population,
baseline FMD was decreased in spite of optimal medical therapy
according to the current guidelines. Although, based on previous
studies, an improvement of FMD might have been expected,
dal-VESSEL was designed as a non-inferiority trial, and while two
co-primary endpoints were pre-specified no corrections for
multiple comparisons were made. There was no evidence of
impairment in endothelial function with dalcetrapib either at 12
or at 36 weeks, but we could also not confirm the beneficial
effects of dalcetrapib reported in a small pilot study22 or with
reconstituted HDL17 and niacin,49 although with 476 patients
enrolled dal-VESSEL would have been powered to show a possible
superiority of dalcetrapib when compared with placebo on FMD as
well. Drugs improving clinical outcome such as statins and
ACE-inhibitors also improve FMD. However, there are exceptions
Figure 3 Change in 24 h ambulatory systolic (A) and diastolic (B) blood pressure after treatment with placebo (n ¼ 237) or dalcetrapib
(n ¼ 235). Data are box-whisker plots+ 1.5 times the interquartile range.
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from this rule, such as estrogens50 and vitamins51,52, which partially
limit the predictive value of FMD for the ongoing outcome trials.
It is unlikely that the neutral effects of dalcetrapib on FMD are
due to methodological issues. Great efforts were made to train
and certify sonographers involved in the 19 centres and to
standardize the methodology for endothelial function testing. All
sonographers underwent a structured training programme and
were certified by a central core lab. Flow-mediated dilatation
was performed according to a standardized protocol using espe-
cially constructed arm rests and probe holders. Furthermore, the
study was overseen by a quality-control programme resulting in
an unprecedentedly high level of reproducibility, equivalent to
that seen in an expert laboratory. Ultrasound scans were read in
a blinded fashion by highly experienced physicians in the core lab
who were not involved in data acquisition.
It is possible that the increase in HDL-C with dalcetrapib was
insufficient to improve FMD in this high-risk population as has
been observed in a previous study.22 Indeed, with intravenously
applied reconstituted HDL, improvement of FMD was accompan-
ied by much higher increases in HDL-C (75%).17 Our patients had
moderate impairment of FMD at baseline so that the measure-
ments should have been able to detect both adverse and beneficial
effects of treatment. In the dal-VESSEL trial, it is noteworthy that,
despite a 30% increase in HDL-C, the neutral effects of dalcetrapib
on FMD were paralleled by a lack of change in the circulating levels
of markers of inflammation and oxidative stress such as MPO and
hs-C-reactive protein. Interestingly, in the recent DEFINE study
with anacetrapib, a much larger elevation in HDL-C was accom-
panied by no significant change in plasma C-reactive protein
levels (from 1.4 to 1.5 mg/L). As in patients with CHD or other
inflammatory conditions, HDL-C becomes dysfunctional and
reduces rather than stimulates NO release, the inability of the
current CETP inhibitors to suppress markers of inflammation
needs further attention.16,53
In the ILLUMINATE trial, torcetrapib increased systolic blood
pressure by about 5 mmHg,7 an effect which is thought to have
contributed to the observed increased mortality. In dal-VESSEL,
ABPM at 4 weeks was therefore a primary outcome measure
and was analysed blindly in a core laboratory. Importantly,
neither systolic nor diastolic BP changed significantly with
dalcetrapib confirming that dalcetrapib is different from
torcetrapib and that hypertension is not a consequence of
CETP inhibition itself.
The findings of the dal-VESSEL trial are reassuring in terms of
the safety of this new agent. They support the continuation of
research programmes studying agents that act on CETP, particular-
ly to examine the longer-term effects of these agents on
atherosclerosis plaque measures and clinical outcomes. dal-
PLAQUE (clinicaltrials.gov number NCT00655473), and
dal-OUTCOMES (clinicaltrials.gov number NCT00658515)27 will
be informative and indicate the impact of agents that act on
CETP on both atherosclerosis evolution and CV events.
Figure 4 Changes in lipoprotein levels in patients treated with placebo ( ) or dalcetrapib ( ). Data are mean+ SD.
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